Pfizer has taken a step closer to developing ponsegromab into a first-in-class treatment to help cancer patients regain lost weight.
ESMO 24: Pfizer To Take Cancer Weight Gain Drug Into Phase III
Pfizer will talk to regulators about pivotal study designs in cachexia following promising ponsegromab Phase II data, with results from a separate study in heart failure also coming soon.
